ATRX and central nervous system cancer: Although there was no significant difference between ATRX loss and ATRX expression in the cohort of patients with grade II or grade III tumors (Figure 5A, 5B), ATRX loss was associated with longer progression-free survival in patients with grade II/III oligoastrocytomas or grade II/III gliomas (Figure 5C, 5D).